In recent years, combination therapy primarily comprising cancer immunotherapy and multi–tyrosine kinase inhibitors (TKIs) targeting the vascular endothelial growth factor (VEGF) signaling pathway has been established as the standard treatment for HCC. The gene discussed is VEGFA; the disease is cancer.